AMRN

Amarin News

Best deals to access real time data!
CHART Trader
Monthly Subscription
for only
$30.66
Canadian Level 1 + USA
Monthly Subscription
for only
$38.05
Small Cap Basic
Monthly Subscription
for only
$33.03
VAT not included
Company Name Stock Ticker Symbol Market Type
Amarin Corp PLC AMRN NASDAQ Depository Receipt
  Price Change Change Percent Stock Price Last Traded
0.08 1.76% 4.62 19:59:58
Open Price Low Price High Price Close Price Prev Close
4.57 4.56 4.75 4.595 4.54
more quote information »

Recent News

Date Time Source Heading
5/04/202107:00GLOBEClinical Data and Other Research Results Regarding VASCEPA®..
4/29/202107:31SEEKAmarin reports decline in Q1 revenue ahead of European..
4/29/202106:36EDGARQuarterly Report (10-q)
4/29/202106:16SEEKAmarin EPS beats by $0.07, misses on revenue
4/29/202106:10GLOBEAmarin Reports First Quarter 2021 Financial Results and..
4/29/202106:00GLOBEAmarin Announces Planned Retirement of Joseph T. Kennedy,..
4/28/202113:06SEEKAmarin Q1 2021 Earnings Preview
4/22/202111:22SEEKUK approves Amarin's Vazkepa for cardiovascular risk..
4/22/202110:53GLOBEAmarin Receives Great Britain Marketing Authorization for..
4/20/202106:05GLOBEAmarin to Report First Quarter Results and Host Conference..
4/17/202109:50GLOBEVASCEPA® (Icosapent Ethyl) Reported to Impact Vulnerable..
4/13/202115:05TRMNAmarin: Could the New CEO Help Vazkepa’s European Push?
4/13/202108:08SEEKAmarin falls as new CEO may mean M&A less likely in the near..
4/12/202116:36SEEKAmarin CEO John Thero to retire
4/12/202116:30GLOBEAmarin Announces CEO Succession Plan
4/06/202106:05GLOBEAmarin Commences Commercial Initiatives for VAZKEPA in..
3/30/202107:42SEEKAmarin wins EU approval for icosapent ethyl to treat..
3/30/202106:24GLOBEAmarin Receives European Commission (EC) Approval for..
3/29/202110:33SEEKAmarin announces clinical recommendations for Vascepa in..
3/29/202107:00GLOBEFifteen Medical Societies Now Recommend Icosapent Ethyl to..
3/24/202106:45IHNWNextech AR (OTCQB: NEXCF) Doubling Sales - Emerging Growth..
3/17/202111:55SEEKHLS Therapeutics highlights promising VASCEPA data analysis
3/17/202111:30GLOBEVASCEPA® (Icosapent Ethyl) Found in Prespecified and Post..
2/25/202109:48SEEKAmarin Q4 results led by strong Vascepa sales
2/25/202106:07EDGARCurrent Report Filing (8-k)
2/25/202105:58SEEKAmarin EPS beats by $0.04, beats on revenue
2/25/202105:55GLOBEAmarin Reports Fourth Quarter and Full Year 2020 Financial..
2/24/202111:55SEEKAmarin Q4 2020 Earnings Preview
2/22/202106:18IHNWNextech AR (OTCQB: NEXCF) $13 million Deal, Guidance to..
2/18/202106:05GLOBEAmarin to Present at Two Upcoming Investor Conferences
2/17/202108:05GLOBEAmarin to Report Fourth Quarter and Full Year 2020 Results..
2/12/202106:26IHNWNextech AR (OTCQB: NEXCF) 2021 Guidance $50-60 Million..
2/09/202107:00GLOBEAmarin Provides Update on VASCEPA® (Icosapent Ethyl)..
1/29/202117:01EDGARCurrent Report Filing (8-k)
1/29/202112:51GLOBEAmarin Receives Positive CHMP Opinion for Icosapent Ethyl..
1/28/202106:30PRNCAVASCEPA® (Icosapent Ethyl) Receives Further Inclusions in..
1/25/202119:35GLOBEAmarin Expands Cardiovascular Risk Reduction Patent..
1/21/202116:30GLOBEIcosapent Ethyl Included in the Chinese Society of..
1/07/202108:00IHNWThe FDA Calendar Review Dates Can Play a Big Role in Timing..
1/07/202106:16EDGARCurrent Report Filing (8-k)
1/07/202106:05GLOBEAmarin Provides Preliminary 2020 Results and 2021 Outlook
1/04/202106:05GLOBEAmarin to Present at 39th Annual J.P. Morgan Healthcare..
12/14/202005:00GLOBEAmarin Highlights Multiple VASCEPA® (Icosapent..
12/12/202021:30GLOBEAmarin Reports Encouraging Efficacy and Safety Results from..
12/07/202007:00GLOBEVASCEPA® (Icosapent Ethyl)-Related Scientific Findings to Be..
11/30/202019:54GLOBEAmarin Files Patent Infringement Lawsuit Against Hikma
11/24/202006:05GLOBEAmarin to Present at Piper Sandler’s 32nd Annual Healthcare..
11/19/202018:30GLOBEAmarin Shares Topline Data from Partner’s Pivotal Phase 3..
11/18/202007:00GLOBEMultiple New VASCEPA® (Icosapent Ethyl)-Related Scientific..
11/13/202010:00GLOBEVASCEPA® (Icosapent Ethyl) Found to Significantly Reduce..
See more news about this stock »


Your Recent History
NASDAQ
AMRN
Amarin
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.